|
|
| ¹«·á À̸ÞÀÏ @cell-signaling °èÁ¤ ¸¸µé±â |
|
|
Designed
by Heidi-Dream |
|
|
|
´ë»çÁõÈıº ¹× ¼¼Æ÷ ½ÅÈ£Àü´Þ ¿¬±¸½Ç (Matabolic Syndrome and Cell Signaling Laboratory)
|
|
|
|
|
| ¡á Home > °øÁö»çÇ× |

 |
| 2014³â "±Û·Î¹ú ¸ÞµðÄ® µð½ºÄ¿¹ö¸®"¿¡ ¼±Á¤µÇ¾ú½À´Ï´Ù |
cell
| 03-18 |
| |
|
À̹ø ¿¬±¸¼º°ú´Â ¼¼Æ÷»ý¹°ÇÐºÐ¾ß ±¹Á¦ÇмúÁöÀÎ ¡®¼¼Æ÷½ÅÈ£Àü´Þ (Cellular Signalling)¡¯ÀÇ 2¿ùÈ£¿¡ °ÔÀçµÇ¾úÀ¸¸ç, »õ·Î¿î ¾ËÄÚ¿Ã ÀÇÁ¸¼º Áö¹æ°£ Ä¡·áÁ¦·Î¼ÀÇ °¡´É¼ºÀÌ ÀÎÁ¤µÇ¾î ½Å¾à »ó¾÷È ¹× ½Å¾àÈĺ¸ ¹ß±¼À» ¸ñÀûÀ¸·Î ¼³¸³µÈ ±¹Á¦Àû ´ÜüÀÎ ¡®±Û·Î¹ú ¸ÞµðÄ® µð½ºÄ¿¹ö¸®¡¯ÀÇ ½Å¾à°³¹ßºÐ¾ß (4¿ù È£)¿¡µµ ¼±Á¤µÆ´Ù.
From: Dr. David Levy <david.levy@globalmedicaldiscovery.com>
Date: Mon, Mar 17, 2014 at 9:21 PM
Subject: {Beta}-Lapachone alleviates alcoholic fatty liver disease in rats
To: insulin@cnu.ac.kr
Dear Dr. Park,
We are pleased to let you know that our Target Selection Team at Global Medical Discovery has identified your recent publication: {Beta}-Lapachone alleviates alcoholic fatty liver disease in rats as a Key Scientific Article contributing to excellence in biomedical research. We would therefore like to feature it in our next edition of Global Medical Discovery Series.
Global Medical Discovery alerts the scientific, clinical and industrial community to innovative papers dedicated to investigating causes and discovering cures for major diseases and debilitating illnesses (for this week edition, click here). Global Medical Discovery is viewed almost 585,000 times each month by our audience of academic, clinical and industrial R&D Scientists and it is featured on the intranets of a growing number of the top 50 Biotechnology and Pharmaceutical companies as well as major academic institutions.
Papers featured by Global Medical Discovery [ISSN 1929-8536] gain extensive exposure. This is good for us since our initial aim was to establish an environment that helps advance medical discovery and accelerate drug development. We also believe that high quality creative research deserves recognition and perhaps more importantly, exposure through Global Medical Discovery is therefore also good for you and your organization since this provides a showcase for key studies such as yours. This exposure has the added benefit of encouraging industrial funding and licensing.
Please do take the time to explore best papers featured at Global Medical Discovery based on the quality of research and its potential impact: http://globalmedicaldiscovery.com. Please don¡¯t hesitate to contact me if you need any further information.
Respectfully,
David Levy, PhD EMBA
VP Scientific affairs, Global Medical Discovery Ltd
Ottawa, K4A 3X8, Ontario, Canada
Tel (+1) 613 878 3745
Email: David.Levy@GlobalMedicalDiscovery.Com
Web: http://globalmedicaldiscovery.com
=======================================================
CONFIDENTIALITY NOTICE
This communication, and the information that it contains: (a) is intended for the person(s) or organization(s) named above or their agents and for no other person or organization and (b) may be confidential, legally privileged and protected by law. Unauthorized use, copying or disclosure of any of it may be unlawful. If you have received this communication in error, please contact us immediately by email, telephone or facsimile.
|
|
|
| |
|
|
|
Matabolic Syndrome and Cell Signaling Laboratory in Institute for Cancer Research Department of Pharmacology, College of Medicine, Chungnam National University
266 Munhwa-ro, Jung-gu, Daejeon, 35015, South Korea Tel: +82-42-280-6768 Fax: +82-42-585-6627 COPYRIGHT ¨Ï 2009 Metabolic Syndrome and Cell Signaling Laboratory, ALL RIGHTS RESERVED.
|
|
|